Literature DB >> 22023558

Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: a case control study from China.

H Xu1, L Li, W-J Huang, L-X Wang, W-F Li, W-F Yuan.   

Abstract

Patients with severe chronic obstructive pulmonary disease (COPD) are at higher risk of developing invasive pulmonary aspergillosis (IPA). However, there are limited data for this disease. To evaluate risk factors and the clinical characteristics of IPA in COPD patients, we conducted a hospital-based, retrospective case-control study of 30 COPD patients with IPA and 60 COPD control patients without IPA. Patients in the case group were significantly more likely to have concurrent co-morbidities than controls. Of the IPA patients, 65.4% had worsening radiological findings vs. 11.4% in the control group (p<0.001). IPA in COPD was associated with a higher proportion of mechanical ventilation (43.3% vs. 5%; p<0.001), a longer hospital stay duration (45.8±39.1 days vs. 18.4±11.8 days; p<0.001), and higher mortality (43.3% vs. 11.4%; p<0.001). Systemic use of steroids in the stable phase, treatment with three or more antibiotics during hospitalization and antibiotic treatment longer than 10 days were independent risk factors associated with IPA. COPD patients with obvious dyspnoea, antibiotic-resistant lower respiratory tract infection and repeated detection of Aspergillus in sputum should be considered for the possibility of IPA.
© 2011 The Authors. Clinical Microbiology and Infection © 2011 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22023558     DOI: 10.1111/j.1469-0691.2011.03503.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  31 in total

1.  Serious fungal infections in Egypt.

Authors:  S M Zaki; D W Denning
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-02-17       Impact factor: 3.267

2.  Clinical in vestigation of misdiagnosis of invasive pulmonary aspergillosis in 26 immunocompetent patients.

Authors:  Rong-Rong Zhang; Su-Fang Wang; Huai-Wei Lu; Zhi-Hua Wang; Xiao-Ling Xu
Journal:  Int J Clin Exp Med       Date:  2014-11-15

3.  Misdiagnosis of invasive pulmonary aspergillosis: a clinical analysis of 26 immunocompetent patients.

Authors:  Rongrong Zhang; Sufang Wang; Huaiwei Lu; Zhihua Wang; Xiaoling Xu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

4.  Immunity status of invasive pulmonary aspergillosis patients with structural lung diseases in Chinese adults.

Authors:  Shuo Liang; Rong Jiang; Hai-Wen Lu; Bei Mao; Man-Hui Li; Cheng-Wei Li; Shu-Yi Gu; Jiu-Wu Bai; Jin-Fu Xu
Journal:  J Thorac Dis       Date:  2017-02       Impact factor: 2.895

Review 5.  Respiratory Mycoses in COPD and Bronchiectasis.

Authors:  Pei Yee Tiew; Micheál Mac Aogáin; Soo Kai Ter; Stefano Aliberti; James D Chalmers; Sanjay H Chotirmall
Journal:  Mycopathologia       Date:  2021-03-11       Impact factor: 2.574

6.  An estimate of the burden of serious fungal diseases in Greece.

Authors:  M N Gamaletsou; M Drogari-Apiranthitou; D W Denning; N V Sipsas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-04-16       Impact factor: 3.267

7.  Serious fungal diseases in the Republic of Uzbekistan.

Authors:  S A Tilavberdiev; D W Denning; N N Klimko
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-03-14       Impact factor: 3.267

8.  Serious fungal infections in Pakistan.

Authors:  K Jabeen; J Farooqi; S Mirza; D Denning; A Zafar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-02-04       Impact factor: 3.267

9.  An invisible threat: mutation-mediated resistance to triazole drugs in Aspergillus.

Authors:  Cau D Pham; Shawn R Lockhart
Journal:  Curr Fungal Infect Rep       Date:  2012-12-16

10.  Role of galactomannan determinations in bronchoalveolar lavage fluid samples from critically ill patients with chronic obstructive pulmonary disease for the diagnosis of invasive pulmonary aspergillosis: a prospective study.

Authors:  Hangyong He; Lin Ding; Bing Sun; Fang Li; Qingyuan Zhan
Journal:  Crit Care       Date:  2012-07-27       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.